1. What is the Chemxpert database?

Chemxpert database is a techno-commercial information platform developed and operated by Lifescience Intellipedia Pvt. Ltd. Our data provides valuable insights regarding sourcing, marketing, development, and regulatory functions for the entire Lifescience industry. The different industries covered by our data encompass APIs, FDFs, pharma intermediates, paints, dyes, polymers, biotechnology, biochemical, food additives, nutraceuticals, etc.

2. How can I subscribe to the Chemxpert database?

You can gain access to the Chemxpert database after subscribing to it by visiting this link: - https://chemxpert.com/pricing

3. How many countries' data is available on your portal?

The Chemxpert database covers more than 200 countries. We are working in the direction of expanding our data coverage in more countries.

4. What are the different sources you use for obtaining information?

The different sources we use for data collection are as follows: - • Primary researc • DMF, ANDA, & CEP list • Conferences, Exhibitions, & Tradeshow • Company annual reports • DMF, ANDA, & CEP list • Subject matter experts & KOL survey. Apart from these, our other valuable sources include application-wise manufacturers list, subscribed and non-subscribed databases, corporate partners, US FDA Orange book, publicly available sources, industry associates, national statistics, regulatory websites, etc. You can gain access to the Chemxpert database after subscribing to it by visiting this link: -https://chemxpert.com/sources

5. What is the expected time for account activation?

Your Chemxpert account will be activated instantly if the payment is made through our website. If you choose to use RTGS, NEFT, or IMPS systems for payment, your account will be activated within 24 hours.

25 Sep 2024
Admin
News Article

Nicox, and Glaukos Ink Exclusive NCX 1728 Research and Global Licensing Option Agreement

Overview

Nicox SA, an international ophthalmology company, announced that it has entered into an exclusive research and license option agreement with Glaukos Corporation for NCX 1728, Nicox’s novel nitric oxide (NO)-donating phosphodiesterase-5 (PDE5) inhibitor. Glaukos is a US ophthalmic pharmaceutical and medical device company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases.

Statement Form the CSO: Nicox

“Glaukos possesses expertise in the treatment of ophthalmic disorders and has unique drug delivery capabilities which could optimize NCX 1728 for uses including reduction of intraocular pressure, neuroprotection and as a potential treatment for retinal diseases.”
“Glaukos is therefore an ideal partner to accelerate the research and development of this unique compound and deliver on its therapeutic potential. We look forward to working with Glaukos to evaluate the use of this novel molecule in multiple different indications.” said Doug Hubatsch, chief scientific officer of Nicox.

Terms of the Agreement

Under the terms of the agreement, Glaukos will fund the evaluation of NCX 1728 in a preclinical research program agreed between Nicox and Glaukos.
The program will explore indications for the treatment of glaucoma, including neuroprotection, and in the treatment of retinal diseases, with the activities being overseen by a Joint Steering Committee.
Glaukos has an option to license NCX 1728 on an exclusive global basis for development in these ophthalmic conditions, which can be exercised within certain specified periods, the first of which is in 12 months.

The Pre-Agreed Term

It would initiate upon signature of a license agreement following Glaukos’s exercise of its option to license, include standard economic provisions for a license agreement of this nature.

About NCX 1728

NCX 1728, an NO-donating PDE5 inhibitor, is the lead compound of a new class of NO-donating molecules in which the NO-mediated effects are enhanced and prolonged by concomitant PDE5 inhibition in the same molecule.
PDE5 inhibition has been previously shown to enhance the efficacy and prolong the duration of NO-mediated effects.

About Nicox SA

Nicox SA is an international ophthalmology company developing innovative solutions to help maintain vision and improve ocular health.
Nicox’s lead programme in clinical development is NCX 470 (bimatoprost grenod), a novel nitric oxide-donating bimatoprost eye drop, for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension.

Let’s apply Data-Driven Pricing to Your APIs

Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.

Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.

Start using market intelligence today and allow yourself to be in control in the API market.

Check it out today and make more informed sourcing decisions! Learn More!